NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-08-31
Reading BMY? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Intact: The reason to own it still holds.
Bristol Myers Squibb grows revenue around $46.6 billion in 2026. Earnings per share reach about $6.20. Profit margins stay near 69.5%. The company benefits from strong drug pipelines and partnerships.
Revenue growth could slow below analyst expectations. Profit margins might compress due to rising costs. Innovation risks and competition could hurt future earnings.
The market prices in about -3% revenue growth and the stock trades roughly 11% below our fair value near $65. We see potential for modest growth and margin stability above these expectations.
Breaks if: EPS falls below $5.90 in FY26
Breaks if: gross margin falls below 67% in FY26
Breaks if: major clinical trial failures or partnership dissolutions
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a stable management team. The current thesis state is intact, supported by recent strong financial performance and a focus on growth.
The market seems to price BMY as cheap compared to its peers, with a low expectations gap. There is no indication of fragility in the current market regime.
Management's focus on driving growth through its Growth Portfolio is showing results, with consistent double-digit revenue growth. However, the mixed status of capital allocation indicates some uncertainty in cash flow management.
The thesis hinges on maintaining growth momentum in the Growth Portfolio and the performance of sector bellwethers like LLY, JNJ, and ABBV. Any negative shifts in guidance or economic indicators could impact sentiment.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat and raised guidance support the read. However, a revived lawsuit poses a threat to financial stability and growth objectives.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: annual revenue falls below $45 billion in FY26
Overall, BMY appears to be in a stable position for the next 1 to 3 years, but it must navigate potential risks carefully. Not investment advice.
